Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with high resolution.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.

The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain can be accurately diagnosed, prevented, and treated. To that end, the McKnight Endowment Fund for Neuroscience invites Letters of Intent for its 2018 McKnight Technological Innovations in Neuroscience awards. The program encourages and supports scientists working on the development of novel and creative approaches to the understanding of brain function. McKnight is interested in how a new technology may be used to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. Because the program seeks to advance and enlarge the range of technologies available to the neurosciences, research based primarily on existing techniques will not be considered. A goal of the Technological Innovations awards is to foster collaboration between the neurosciences and other disciplines; therefore, collaborative and cross-disciplinary applications are explicitly invited.

This Funding Opportunity Announcement (FOA) issued by the Fogarty International Center (FIC) seeks to stimulate innovative ideas and impactful research to better understand the complexities around developing appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for HIV-associated non-communicable diseases (NCDs) in Low and Middle-Income Countries (LMICs). Specifically, this initiative will support research in the following areas: a) Basic sciences to address etiopathogenesis of NCDs in Persons Living with HIV (PLWH); b) Aging process in PLWH; c) Diagnostics tools for early detection of NCDs in PLWH; d) Therapeutic interventions to explore optimal drug regimens for PLWH with NCDs; e) Behavioral studies for better quality of life of PLWH with NCDs; and f) Clinical studies for better patient centered care for PLWH with NCDs. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development and assessing feasibility of the proposed studies (https://grants.nih.gov/grants/funding/r21.htm ). It is hoped that this preliminary research will lay the foundation for larger studies that can lead to applications to other organizations or NIH institutes that support HIV-associated NCD research.

TheMacrosystems Biology and NEON-Enabled Science (MSB-NES): Research on Biological Systems at Regional to Continental Scalesprogram will support quantitative, interdisciplinary, systems-oriented research on biosphere processes and their complex interactions with climate, land use, and changes in species distributionatregional to continental scales as well as training activities to broaden participation of researchers in Macrosystems Biology and NEON-EnabledScience. Proposers are encouraged to use NEON resources, and proposals for substantive and innovative NEON-enabled research will be prioritized for funding.Substantive NEON-enabled projects rely on data and/or samples collected by NEON, co-locate research activities at NEON sites, and/or develop tools that will explicitly enhance the processing, use, and/or analysis of NEON data or collections within the context of Macrosystems Biology research questions.

The purpose of this FOA is to solicit applications for research projects to generate reference datasets and to create navigable maps for the study of the spatial and temporal organization of the nucleus, using genomic and imaging data as well as newly developed visualization and integrative analysis tools.

To support the development and application of tools that would enable the monitoring in real-time of the dynamic three-dimensional structure of mammalian genomes and provide insight into how organizing components of 4D genome architecture affect biological processes in live cells.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes the ability to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. FOA Emphasis. The FOA utilizes the R33 mechanism which is suitable for projects where proof-of-principle of the proposed technology or methodology has been demonstrated and supportive preliminary data are available. Proposed projects should offer new tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The emphasis of this FOA is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, screening, clinical diagnosis, treatment, epidemiology, or address issues in cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with high resolution.

To support the development and application of tools that would enable the monitoring in real-time of the dynamic three-dimensional structure of mammalian genomes and provide insight into how organizing components of 4D genome architecture affect biological processes in live cells.

The intent of the FY19 PRARP CSRA is to support innovative or novel efforts to generate research resources, tools, or research efforts for researchers and/or practitioners in health sciences related to the PRARP's mission (see Section II.A, Program Description). The proposed work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the contexts of the PRARP's mission and vision. The research innovations for the FY19 PRARP CSRA are expected to benefit the military, Veteran, and civilian communities. FY19 PRARP CSRA applications should be Innovation- and Impact-based.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Also listed under R21

The ReVector program aims to develop methods to use human skin microbiomes to modulate chemical signatures in order to avoid mosquito attraction and feeding and reduce the threat of mosquito-borne disease to Warfighters. Human skin associated microbes interact with metabolites from the body and influence the personal chemical signature of each individual, making some individuals more attractive to mosquitoes. This program seeks to develop advanced data analytics and microbiome modulation tools for engineering skin microbiomes and provide new options for the readiness and resiliency of military personnel.

This Challenge encourages college and graduate students to develop innovative information dissemination tools, instruments, or devices that help spread evidence-based information about SCD, so that people living with the disease can live better, healthier lives.

The Rheumatology Research Foundation is issuing a notice of special interest (NOSI) to highlight the availability of funds for projects exploring the relationships between rheumatic and musculoskeletal diseases and SARS-CoV-2, the virus that causes COVID-19. The Foundation accepts submissions within the following scientific categories: * Basic Science * Translational Science * Clinical Science * Health Services Research * Patient- or Practice-Centered Research Examples of studies relevant to this NOSI include, but are not limited to: * Immune responses to SARS-CoV-2 and pathogenesis of COVID-19 in patients with RMDs * Influence of DMARDs, biologic agents, or other medications, on SARS-CoV-2 immune responses * Studies of DMARDs or biologic agents used in RMDs on outcomes of SARS-CoV2 infection in animal models or in vitro * Epidemiology, clinical characteristics, and outcomes of CoVID-19 course in patients with RMDs, including the influence of therapeutic agents or other interventions in pragmatic trials * The effects of COVID-19 on access to rheumatology care, including telehealth, digital tools, social determinants of health, etc. * Analyses of the economic impact of COVID-19 on the care of patients with RMDs

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) as a part of its Beau Biden Cancer Moonshot Initiative invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) as Recommendation I: Generation of Human Tumor Atlases. The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, humantumoratlas.org) via the implementation of three-dimensional (3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans. Each project will lead to the multiplexed 3D characterization of at least one cancer transition investigated by the HTAN (pre-malignant to malignant, primary to metastatic, therapy responsive to resistant). The data and analytical tools generated through this FOA will be made available for use by the research and clinical communities through the activities of the HTAN Data Coordinating Center.

The purpose of this funding opportunity is to solicit applications that fully integrate recent innovative advances of in vitro functional genomics tools/technologies and approaches for environmental health and toxicology research. The overall goal of this NIEHS led initiative is to generate proof-of-principle studies incorporating these new in vitro approaches, together with well characterized exposures, to further our understanding of gene-environment (G x E) interactions in complex human disorders.

This Funding Opportunity Announcement (FOA) is intended to address the problem of misidentified cell lines. Many advances in biomedical science have arisen from studies of cultured cell lines, which are widely used for basic research on cell function, as models for disease, and for drug screening.  In most of this research, correct identification of the cell lines used is necessary to replicate experiments.  In addition, in a majority of the projects the cell lines used were chosen because they are predicated to recapitulate biologically important features of the tissue and/or tumor of origin, for example, driver mutations, expression patterns, and functional correlates of the differentiated state of the original tissue. Cell line origins are documented by chain of custody (a continuous chronological record documenting their source, transfer, analysis, and disposition).  However, cell lines in culture are prone to contamination by foreign cells, which may rapidly displace the original cells.  The identity of cultured cells should be routinely verified, but a majority of laboratories do not monitor the identity of their cell lines, and many cell lines are misidentified.  Analyses of cells submitted to major repositories such as the ATCC (American Type Culture Collection) and the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) have found that 15-40% of cell lines submitted by investigators are misidentified, i.e., they have a tissue or species of origin that differs from the one reported.  Similar frequencies of misidentification have been reported by research laboratories that have examined cell line collections.